Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

NCT04131595 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT04131595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04131595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
Lead sponsor
Bavarian Nordic
Phase
Phase 1
Overall status
Completed
Start date
October 7, 2019
Completion date
July 22, 2020
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

equine encephalitis